# Comprehensive Insights into Inflammatory Bowel Disease: Evaluating Patient Quality of Life, Pregnancy Management, Ulcerative Colitis Report

Shivika[1], Shammy Jindal[2], Mahendra Ashawat[3], Dimple Kumari[4]

[1]*Student, Department of pharmaceutical science, Laureate Institute of Pharmacy, Kathog jawalaji, India*

[2]*Associate Professor, Department of pharmaceutical science, Laureate Institute of Pharmacy, Kathog jawalaji, India*

[3]*Professor, Department of pharmaceutical science, Laureate Institute of Pharmacy, Kathog jawalaji, India*

[4]*Assistant Professor, Department of pharmaceutical science, Laureate Institute of Pharmacy, Kathog jawalaji, India*

*Corresponding Author: shivikaparmar427@gmail.com*

Abstract— **To ensure proper treatment of this complex condition, a thorough understanding of the symptoms and diagnostic process for inflammatory bowel disease is required. While Crohn's disease and ulcerative colitis have many similar clinical characteristics, their approaches to care are significantly different. This article discusses the causes of IBD pathogenesis and manifestation in addition to the techniques for diagnosis and work-up to guarantee the correct diagnosis is made. This page also provides a foundation for comprehending the disease's more intricate facets, which will be covered in later sections.**

***Index Terms*—Inflammatory bowel disease, ulcerative colitis, genome coverage's, microsatellites, inflammation, immunosuppressant, immunosuppressive, nationwide retrospective cohort study.**

## 1. Introduction

Both ulcerative colitis and Crohn's disease are long-lasting inflammatory conditions that harm the colon. These conditions are frequently complicated by other gut conditions as well as numerous other chronic and occasionally acute conditions.

IBD can also affect dogs, and it is believed that the immune system, intestinal milieu, host genetics, and environmental factors interact to cause IBD.

An illustration. Compared to people with IBD, who frequently require immunosuppressive therapy, many dogs respond to dietary changes alone. When dietary adjustments are insufficient, some dogs may additionally require therapy with immunosuppressant's and antibiotics.

Manuscript revised July 04, 2024; accepted July 05, 2024. Date of publication July 06, 2024.
This paper available online at www.ijprse.com
ISSN (Online): 2582-7898; SJIF: 5.59

Intestinal biopsies are frequently carried out to determine what type of inflammation is present after ruling out other illnesses that might cause vomiting, diarrhea, and abdominal pain in dogs (lymphoplasmacytic, eosinophilia, or granulomatous).

In a study of 62 UC patients and controls, those in the highest dietary antioxidant group (total antioxidant capacity) had an 89 percent lower risk of UC2 In a study of 58 UC patients and 123

healthy control participants, those in the highest dietary antioxidant group (healthy eating index) had a 66 percent lower risk of UC than the lowest group3.

## 2. Quality Of Life in IBD Patient

We conducted in-depth interviews with 43 patients with ulcerative colitis and 54 individuals with Crohn's disease to understand more about how IBD affected patients' quality of life. (1). Compared to primary gastrointestinal symptoms and impaired emotional function, functional and social difficulties were less common. Patients reported major problems that occurred frequently across five different domains (2, 3). Patients with chon's disease have higher rates of systemic symptoms like weariness. IBD significantly impairs patients' quality of life (4). Many disease activity indicators have been created (1-4), but these indices do not place a significant emphasis on the patient's subjective experience (5). Limitations in job and social activities, home and marriage life, and emotional function have been reported in qualitative and semi quantitative accounts of the issues impacting IBD patients (6). However, a thorough quantitative assessment of the issues people with Crohn's disease and ulcerative colitis (7), as well as the significance of these issues, has not yet been done (8).

### *A. Pregnancy Related Inflammatory Bowel Disease*

For the purpose of examining the relationships between pregnancy and inflammatory bowel illness, the classification Abramson proposed will be used (9). Groups 1 and 2 each have inactive IBD at conception, active IBD (10) at consumption, emerging IBD during pregnancy, and emerging IBD during puerperium (11). However, even in the large series, there are only a tiny number of occurrences in Groups 3 and 4, making it difficult to draw many conclusions from them (12).

### *B. IBD's Impact on Pregnancy*

Table no. 1. Summarizes the results of 1308 pregnancies in women with UC that were documented in 10 important studies (13). The ordinary UC patient has a very great chance of having a healthy, full-term pregnancy, and the overall statistics are equivalent to those of the general population (14).

### *C. Pregnancy's Impact on Ulcerative Colitis*

Table no. 2. Displays the likelihood of relapse in patients with an inactive illness at conception if the series has already been cited in 8 (15). During the twelve months of pregnancy and puerperium, about one-third of patients will relapse (16).

Although the rate varied greatly between various series and might reach as high as 40%, almost a quarter of group 1 individuals suffered a recurrence of CD while pregnant or during the puerperium (17). (18, 19).

It appears that around one-third of group 2 CD patients will improve during pregnancy and puerperium (20), one-third will remain unchanged, and one-third will deteriorate (21).

Table.1.
IBD'S Impact on Pregnancy

| [1] REFERENCE | [2] No. of Pregnancies | [3] Recurrence |
|---|---|---|
| [4] Abramson et al. 1951[1] | [5] 20 | [6] 35 |
| [7] MacDougall 1956[2] | [8] 21 | [9] 10 |
| [10] Crohn et al. 1956[11] | [11] 74 | [12] 54 |
| [13] Banks et al. 1957[13] | [14] 46 | [15] 28 |
| [16] De Dombal et al .1965[4] | [17] 80 | [18] 34 |
| [19] McEwan 1972[12] | [20] 25 | [21] 16 |
| [22] Willoughby & truelove 1980[6] | [23] 129 | [24] 30 |
| [25] Nielsen et al. 1983[15] | [26] 133 | [27] 35 |
| [28] Overall | [29] 528 | [30] 34 |

Table.2.
Pregnancy's Impact on Ulcerative Colitis

| [31] RRFERENCE | [32] No. of pregnancies | [33] Normal babies (%) | [34] Congenital abnormality | [35] Spontaneous abortion (%) | [36] Stillbirth (%) |
|---|---|---|---|---|---|
| [37] Crohn et al. 1956[16] | [38] 84 | [39] 87 | [40] O | [41] 6 | [42] 1 |
| [43] Fielding & Cooke 1970[7] | [44] 98 | [45] 84 | [46] 0 | [47] 13 | [48] 2 |
| [49] Schofield et al. 1970[17] | [50] 34 | [51] 71 | [52] 6 | [53] 24 | [54] |
| [55] De Dombal et al .1965[4] | [56] 60 | [57] 88 | [58] 2 | [59] 5 | [60] 5 |
| [61] Norton & Patterson 1972[18] | [62] 19 | [63] 84 | [64] 0 | [65] 11 | [66] 0 |
| [67] Homan & Thobjarnarson 1976[9] | [68] 42 | [69] 74 | [70] 0 | [71] 17 | [72] 2 |
| [73] Mogadam et al .1981[14] | [74] 222 | [75] 93 | [76] 1 | [77] 3 | [78] 1 |
| [79] Khosla et al. 1984[10] | [80] 80 | [81] 70 | [82] 1 | [83] 27 | [84] 1 |
| [85] Nielsen et al. 1984[19] | [86] 109 | [87] 70 | [88] 0 | [89] 9 | [90] 1 |
| [91] Overall | [92] 748 | [93] 83 | [94] 1 | [95] 12 | [96] |

| [1] REFERENCE | [2] No. of pregnancies | [3] Better (%) | [4] No. of change (%) | [5] Worse (%) |
|---|---|---|---|---|
| [6] Crohn et al. 1956[16] | [7] 30 | [8] 47 | [9] 40 | [10] 13 |
| [11] Khosla et al. 1984[10] | [12] 20 | [13] 35 | [14] 30 | [15] 35 |
| [16] Nielsen et al. 1984[19] | [17] 43 | [18] 26 | [19] 28 | [20] 47 |
| [21] Overall | [22] 93 | [23] 34 | [24] 32 | [25] 33 |

There have been few group 3 and 4 cases described, although it has been asserted that the prognosis for the foetus in Group 3 cases can be bad (22)

*D.* Drugs Used on Pregnancy In *IBD*

• Medication- people with IBD often require medication to control their disease. Below in some general information abouts some of the medications used to treat IBD (23).

- Sulfasalazine- women who wish to become pregnant can continue taking this drug during pregnancy. It does not increase the risk of any complications. FOLIC acid 2mg per day should be taken with this drug (24).
- Antibiotics- These should only be used to treat an active infection since they are rarely necessary in the treatment of IBD (25).5-AMINOSALICYLATE DRGS - studies suggest that the 5-ASA drugs can be taken during pregnancy (26).
- Steroids- Steroids are associated with inc. complication of pregnancy among women with IBD (27).
- Azathioprine- IT can be continued in pregnancy (28).
- Adalimumab- As with infliximab an increase in congenital anomalies has not been reported with Adalimumab (29).

## 3. A National Retrospective Cohort Study on The Impact of Alcoholic Intoxication on The Risk of Inflammatory Bowel

The effect of alcohol on IBD has not been well established, but long-term alcohol use is one of the potential latent risk factors, especially in cases of severe alcohol consumption, like alcohol abuse and intoxication. Alcoholic intoxication or hazardous and harmful alcohol use can cause major GI diseases like gastritis, cirrhosis, hepatitis, and pancreatitis (30).

*A. Data Source*

Data were taken from the whole database of the Taiwan National Health Insurance Program., claims database, the national health insurance research database (31). Over 98% of Taiwan's 23 million citizens were covered by this programme, which was launched in 1995. (32).

*B. Study Population*

We conducted a retrospective population-based cohort analysis to look into the relationship between alcohol consumption and the risk of IBD (33). Two groups of inebriated drinkers were produced. (ICD-9-CM codes 303, 305.0, and V113) between 1999 and 2008, with the index date being the day the diagnosis of intoxication by alcohol was made (34).

The controls for the non-alcoholic intoxication group were randomly chosen from the NHIRD, and they were regularly matched with the patients with alcoholism based on age (per 5y), sex, and index year at a ratio of index date (35). From the index date to the patient's withdrawal from the NHI and IBD event, or December 31, 2011, every trial participant was tracked. (36).

We evaluated the effect of high alcohol use on the likelihood of IBD (37). We determined the proportion of the length of the follow-up period to the total length of hospital stays brought on by alcohol use (38). According to the fabric, we divided the intensity of alcohol intoxication into three categories (39). Additionally, we classified the participants into three groups based on the number of admissions for alcohol-related illnesses throughout the observation period (40).

## 4. Case Report on Ulcerative Colitis

*A. 16 Year Girl*

A feature of ulcerative colitis, a type of IBD, is diffuse colonic mucosal inflammation. UC is a chronic condition that causes unchecked colon inlammation on a recurrent basisThe rectum is consistently impacted by inflammation that progresses from the distal to the proximal clonic segments. The terminal ileum is typically untouched, though some people with advanced illness may have endoscopic signs of "backwash ileitis." SYMPTOMS: Symptoms of newly diagnosed UC or repeated flare-ups typically include diarrhoea and stomach discomfort with blood and mucosa.

Weight loss, tachycardia, fever, anaemia, and intestinal distension are severe cases.

Daignostic: medical history (stool frequency, consistency,blood and mucosa ,noctural diarrhoea,family history).

Clinical examination: concentrated on endoscopy with mucosal biopsies, full blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and ultrasonography. Heartbeat, fever, and a painful abdomen

*B. Case Report*

A 16-year-old female patient with complaints of hemotochezia (two to three episodes per day) was taken to the emergency room of a government general hospital (41). She currently has a fever, abdominal ache, vomiting, and acute epigastric pain after meals (42). The patient has never previously complained of anything comparable, and her entire

medical history—including her menstrual period—was normal (43). The patient was conscious during the general examination, but the icterus was not present (44). Her blood pressure was 110/80 mmHg, and laboratory tests revealed the following:

| [26] PARAMETERS | [27] OBSERVED VALUE |
|---|---|
| [28] HB | [29] 7.0g/dl$^3$ |
| [30] Platelet count | [31] 4,89,000/mm$^3$ |
| [32] Red blood cells | [33] 4.2 106/mm$^3$ |
| [34] White blood cells | [35] 20,000/mm$^3$ |
| [36] Erythrocytes sedimentation rate | [37] 58mm/hr$^3$ |

The deffencial count was normal, AND the order laboratory investigation include: sigmoidoscopy: impression: diffuse erythema, erosion with superficial ulceration involving rectum to descanting colon (45).so the doctor conformed the case as" UC".

The medication include: Iron folic acid 150mg PO od, injection Buscopan IV sos, injection ranitidine 50mg BD, injection ciprofloxacin 200mg IV BD, tablet, bifilac 1.2g PO OD, injection diclofenac 1V SOS. Four days were spent taking the drug. She experienced a headache, fever, and bloody faces on the fourth day's evening. 500mg Tab. PCM PO SOS was administered. Metronidazole 500 mg IV Tid, ciprofloxacin 200 mg IV Bd, diclofenac 1 g IV SOS, and ranitidine 50 mg IV Bd were topped off after four days. and kept taking the rest of the prescription. The patient began seeing symptom improvement after five days. On the fifteenth day, the patient received a discharge prescription and a warning. (46).

## 5. Discussion

Although UC is known to afflict both children and adults worldwide, it is less common in Africa, either as a result of underdiagnoses, incorrect diagnosis, or a lack of ethnic diversity. In South Africa 15, Uganda 16, and Sudan 17, there have been few reports of UC in adults. The significance of this recent case report is further highlighted by the lack of recorded cases in African children (47).

Your gut moves quickly and empties regularly as a result of the inflammation. Ulcers develop as the surface lining of your bowel loses cells. The ulcers may bleed, leak mucous, and additionally (48). Depending on the level of inflammation and the location of the inflammation, ulcerative colitis symptoms can differ (49). It also appears that heredity may play a part in why UC is more prevalent in persons who have family members with the disease. When your immune system tries to fight off an invading virus or bacteria, an aberrant immunological response causes the immune system to attack the cells in your digestive tract (50). However, this family history is uncommon among most UC patients. Intestinal wall thickening, sepsis (blood infection), severe dehydration, toxic mega colon or a rapidly growing colon, uncommon liver illness, and intestinal bleeding are complications. Risk elements Age. If you are between the ages of 15 and 30 or older than 60, your risk is higher than average in people of Ashkenazi Jewish descent. Family history: your risk could be up to 30% higher if you have a close relative with the condition (51).

Medication therapy aims to:

They induce and maintain remission raise the patient's quality of life.

Unless their colon and rectum are surgically removed, many UC patients require ongoing pharmaceutical therapy. Medical practitioners will prescribe biologics also known as anti-TNF therapy, aminoacylates, corticosteroids, immunomodulators, and other drugs based on how successfully they address a patient's symptoms (52). Depending on where the symptoms are in the colon, medical practitioners may suggest a patient undergo an enema, which includes flushing liquid medication into the rectum using a particular water bottle.. The drug effectively cures large intestine inflammation. For those who do not absorb adequate nutrients, medical professionals may advise taking vitamins and nutritional supplements (53). People's usage of complementary and alternative medicine, including the use of probiotics and nutritional supplements, should be discussed in order to help ensure coordinated and safe care. with their healthcare professional (54).

### *A. Linkage And Genome Wide Association Studies of Common Disease to Common Variants from Microsatellites*

The majority of research that attempted to identify genomic areas associated with disease before the convenience of low-cost sequencing and a fully annotated human genome with well-characterized exon and inter sections relied on microsatellite data (59). In the 1990s and the beginning of the 2000s, short tandem repeats, sometimes known as microsatellites as genetic markers were widely employed. When compared to sequencing multiple balletic SNPs (single base-pair changes) simultaneously, sequencing microsatellites was more inexpensive and offered a wider range of allelic variation. Microsatellites amplified using fluorescently labelled primers made linkage testing possible, which involves the inheritance of marker alleles together with phenotype and was usually performed in large families where segregation patterns were investigated. This led to the creation of disease etiology hypotheses.

Several techniques were used to analyses microsatellite data Due to the absurdly high sequencing costs at the time ($2.7B for the first genome assembled by the human genome project (HGP)60), as opposed to $1,000 now, all tried to continuously reduce areas of interest within the genome down to "must-sequence" parts. The most widely used of these approaches were linkage analysis and subsequent linkage disequilibrium mapping (LD mapping). Linkage analyses, which might be parametric or non-parametric, aimed to collect all pertinent inheritance information from pedigrees and test for shared inheritance of chromosomal regions with a trait (61). In order to determine whether the hypothesized inheritance pattern matched a certain model for a gene responsible for a trait and to determine the likelihood of recombination at loci, parametric

linkage analyses were utilized.

Although it presupposes that the disease's inheritance pattern is known, the LOD score technique is the most popular parametric linkage test (62Calculated is the likelihood ratio between the theories that a disease gene is located at a particular locus and that the disease is unrelated to it. Instead, non-parametric techniques compare the counts of common alleles pairwise (63) or in a group (64) within each pedigree to determine whether the inheritance pattern is the consequence of expectation under independent assortment over all pedigrees. In the past, the suggested regions of search from linkage analysis were compressed using LD mapping approaches, which use reference genome data and annotations. These techniques greatly decreased the number of sequences required (65).

The transmission disequilibrium test (TDT), once the idea of units of association was put forth, was frequently used to determine the genetic link between a trio's components and phenotypic (66). Later studies employed modifications of this method, such as the pedigree disequilibrium test, and, when suitable, compared the frequency of variants in patients and controls, but they lacked the power needed to detect or establish a relationship in the case-control setting.

There has been suggested a primary pathogenic mechanism for CD (67). Several startling findings from studies on microsatellites and IBD have motivated efforts to dig further into the genetic underpinnings of the disorder. The first three rare-variant connections with CD-one frame shift and two missense variants in the NOD2 gene were found using microsatellite technology, non-parametric linkage analysis mapping, and the TDT (now canonically accepted as variants causal of CD). These modifications affect the leucine-rich repeat domain of an apaf-1/Ced-4 apoptotic regulator generated in monocytes. The knowledge that this domain acts as a receptor for components of microbial pathogens served as the impetus for the investigation. A different concurrent investigation identified a cytosine insertion (3020insC) in the same gene using the TDT and low-n case-control approach (68).

The study shows that when nuclear factor NF-kB is activated by wild-type NOD2, it responds to bacterial lipopolysaccharides. Therefore, this induction was lacking mutant NOD2. Due of the impending data increase, studies like this highlighted the possibility of additional uncommon variant findings in IBD.

In the years after the millennium, sequencing prices surpassed Moore's Law resulting in an explosion of study-ready genomic data. The HGP, which catalogued the vast majority of bases that are consistent across populations, was largely responsible for providing a "universal reference" upon which genes were discovered and designated utilizing this new data. But the Hap Map (69) project was crucial to the following round of analysis. Which categorized population-specific variation. The project discovered 3.4 million SNPs in total across all stages of its execution, catalyzing improvements in SNP assay methods (70).

Although better maps of human genome variation, like those proposed by the 1000 Genomes consortium (15 million SNPs, 1 million short insertions/deletions, and 20,000 structural variants), would emerge later, Hap Map enabled and made popular some of the first large-scale genetic studies of complex diseases (28-30).

These research, known as genome-wide associate studies, involved the independent association testing of 100–1000 million SNPs against one or more phenotypes (GWAS). The initial GWAS explored whether or not there were differences between the trait means of any genotype group using 2 into 2 allele-count contingency tables and techniques like the fisher exact test and the permutation test (71); these preliminary analyses did not take covariates into account. When it was necessary to divide contingency tables into different strata (e.g., by genotype or ancestry), the Cochran-Mantel-Hansel chi-squared test (72) was employed to evaluate whether signals were common across strata (71). GWAS today frequently employ techniques to take variables into account while testing. For instance, covariates like age, sex, and genetic main components can be taken into account using generalized model lines (e.g., logistic regression for binary characteristics and linear regression for quantitative traits) (which serve as substitutes for ancestry). They are currently the most widely used genetic association technique as a result. While genotypic association tests look at the relationship between different genotype classes, allelic association tests look at the relationship between a specific allele and phenotype (such as additive, dominant, and recessive). Additionally, multiplexing effects between phenotype and alleles exist (73). Multiple hypothesis testing modification to the data is typically undertaken to account for the false discovery rate, and the strongest findings are statistically replicated in separate experiments or by utilizing meta-analysis approaches across studies.IBD was the phenotype of interest in a number of early, high-impact GWAS. The IL23R gene, which codes for On chromosome Ip31, there is a receptor for the proinflammatory cytokine interleukin-23. A very significant connection between CD and this gene was found by Duerr et al. Additional non-coding IL23R correlations in several cohorts of CD patients further backed the gene's rare coding variant (rs11209026, c1142G>a, p. Arg381Gin), which has been shown to have protective benefits. The intragenic region (10q21.1), a coding mutation in ATG16LI expressed in intestinal epithelial cell lines, and additional variations in CARD15, PHOX2B, NCF4, and FAM92B were frequently associated with CD, according to further studies (74).

With a combination of regulations based on the population and the family, Barrett et al. duplicated the results in 3,664 separate cases utilising three CD studies (3,230 cases, 4,829 controls). This analysis confirmed 11 previously reported loci, while giving genome-wide strong evidence for 21 additional loci (STAT3, JAK2, ICOSLG, CDKALI, ITLNI among them).Two years later, using a similar methodology and more data, The number of CD-association loci increased from 32 to

71 thanks to the efforts of the same group (75). The team tracked the strongest association signals in 15,694 cases, 14,026 controls, and 414 parent-offspring trios in their meta-analysis of six CD GWAS (6,333 cases, 15,056 controls). Important essential genes like SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENNDIB, BACH2, and TAGAP were also highlighted by the procedure. This led to the identification of 30 fresh, significant, genome-wide susceptibility loci. The success of the CD GWAS was followed quickly by the discovery of UC risk alleles. Candidates include the immunoglobulin receptor genes FCGR2A, 5pI5, 2p16 ORMDL3 (ovomucoid 1- like 3). were discovered using two different GWAS, while a meta-analysis of six UC GWAS, consisting of 6,687 cases and 19,718 controls, revealed 29 additional GW significant risk loci (including ILIR2, IL8RA-IL8RB, IL7R, DAP, PRDMI, JAK2, IRF5, GNA12, and LSP1) (76).

*B. Common Diseases from Targeted to Whole - Exome And - Genome Sequencing Studies*

After some time, scientists were able to implement whole-exam sequencing (WED, -29 Mb) or whole-genome sequencing (WGS, 100 Mb) without having to make educated guesses about which sections of the genome should be studied (77). The development of more effective made these techniques possible.

The HiSeq X platform is one example of a sequencer (capable of sequencing 16 human genomes in 3 days with 30x coverage)

a) the application of algorithms designed specifically for aligning all short readings.

b) Different calling techniques

Similar growth in formation density and coverage was observed for annotation databases that offered data such as variant pathogenicity prediction (e.g., SIFT, GERP, POLYPHEN, CADD, and CLIN Var) (78). Prior to experimental validation in murine or other models, this variations annotation system gives researchers a sense of the pathways in which potential variants are implicated. Finding the responsible alleles for hyper polygenic diseases like IBD has never been easier thanks to parallel developments in variant sequencing, calling, and annotation and ever-growing sample sizes.

To deal with the issues that come with datasets of this kind, methods have also been devised. While the foundation of association testing (as used in programmers like SNPTEST and PLINK) has mostly not changed over time, other fields have developed quickly to make up for the lack of power in rare-variant association studies (RVAS). Techniques at the design-level and those at the methods-level have made it possible for RVAS to proliferate in bio banks. These methods increase the ability to identify genetic variations between patients and controls.

Extreme phenotype sampling (choosing samples from the extremes of quantitative trait distribution), population isolate studies (finding variants with a lack of concordance in allele frequencies with other populations, due to high drift and low diversity), co-segregate with the condition of interest, and trio studies (using the transmission disequilibrium test to identify candidate rare variants) are a few examples of design-level variant techniques (79). By collecting uncommon variations within "units of association" utilising labels like gene annotations or functional characterizations, methods-level procedures, also known as gene-based tests, navigate increased multiple testing burden and decreased statistical power. (80)

There are two basic types of gene-based testing: burden and variance-component tests. By aggregating and comparing the disease prevalence between the groups, burden tests determine whether rare -variant carriers in a gene have phenotypes that are similar to those of the wild type (e.g., CAST, CMC, VT). However, they become less effective when combined with numerous non-casual or opposing impact versions. Variance component tests suffer from the opposite issue, losing power when a significant portion of the rare variants in a block are truly casual and influence the phenotype in the same direction. These tests take the opposite effect on the phenotype into account (and consider the phenotypic variance rather than the mean or prevalence).

A variance-component test that can handle covariate adjustment, study design, and various variant prioritization/weighting procedures is the Sequence Kernel Association Test (SKAT) method. A more recent technique called SKAT-O aims to maximize finding power under various genomic architecture models by combining parts of burden and variance-component testing. Meta-analyses across multiple studies (as implemented via the CMH test, or in an optimized package such as METASOFT) have gained popularity as a method to priorities candidate variants because researchers cannot feasibly experimentally validate all of the ballooning number of reported complex disease associations in the literature to date (81).

Numerous novel IBD genes and variations necessary for pathogenesis have been found thanks to the most recent WES and WGS investigations. One team used low-coverage WGS to analyses 73.5 million variants in 3,280 IBD patients and 3,652 population controls. They then imputed these sequences into new and/or existing GWAS cohorts and tested for associations at 12-million variant sites in a total of 16,432 cases and 18,843 controls. They discovered a significant missense variant in ADCY7 with a frequency of 0.6 percent that doubles the risk of UC (6). 23,305 participants in a second GWAS revealed previously unknown and newly hypothesized defective and inflammatory regulator genes (82). The incremental knowledge of the etiology of complex diseases will continue to show promise as sequencing depths, genome coverage's, and variation annotation density rise (83).

## 6. Conclusion

In this instance, a 16-year-old female patient was taken to the hospital with hematochezia, fever, epigastria pain, and acute

post-meal vomiting. due to incorrect diet, stress, protein supplements, and a lack of sufficient nutrition (57). The patient is not consuming enough protein, other nutrient supplements, vitamin and c rich meals, eggs, green leafy vegetables, fish, meat, etc. Pharmacists' remedies for this case study include advising the patient to consume fiber- and lactose-rich foods. Compared to adults, children exhibit different characteristics and patterns of these illnesses. To prevent further negative effects on growth and nutritional balance, early diagnosis considerations are crucial. In the overall management of IBD, nutritional factors are crucial.

While EEE therapy is the preferred treatment to elicit remission of CD, general growth and nutrition monitoring are important aspects of continued maintenance. Along with the awareness of the significance of the intestinal micro flora in the etiology of IBD, further research on the effectiveness of medications such antibiotics is likely to go forward (58).

## References

[1]. Abramson D, Jankelson IR, Milner LR. Pregnancy in idiopathic ulcerative colitis. American Journal of Obstetrics and Gynecology. 1951 Jan 1;61(1):121-9.
[2]. Macdougall I. Ulcerative colitis and pregnancy. The Lancet. 1956 Sep 29;268(6944):641-3.
[3]. Banks BM, Korelitz BI, Zetzel L. The course of nonspecific ulcerative colitis: review of twenty years' experience and late results. Gastroenterology. 1957 Jun 1;32(6):983-1012.
[4]. De Dombal FT, Watts JM, Watkinson C, Goligher JC. Ulcerative colitis and pregnancy. Journal of Occupational and Environmental Medicine. 1966 Aug 1;8(8):453.
[5]. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980 Jun 1;21(6):469-74.
[6]. Fielding JF, Cooke WT. Pregnancy and Crohn's disease. Br Med J. 1970 Apr 11;2(5701):76-7.
[7]. De Dombal FT, Burton IL, Goligher JC. Crohn's disease and pregnancy. Br Med J. 1972 Sep 2;3(5826):550-3.
[8]. Homan WP, Thorbjarnarson B. Crohn disease and pregnancy. Archives of Surgery. 1976 May 1;111(5):545-7.
[9]. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut. 1984 Jan 1;25(1):52-6.
[10]. Crohn BB, Yarnis H, Crohn EB, Walter RI, Gabrilove LJ. Ulcerative colitis and pregnancy. Gastroenterology. 1956 Mar 1;30(3):391-403.
[11]. Miller JP. Inflammatory bowel disease in pregnancy: a review. Journal of the Royal Society of medicine. 1986 Apr;79(4):221-5.
[12]. Webb MJ, Sedlack RE. Ulcerative colitis in pregnancy. Medical Clinics of North America. 1974 Jul 1;58(4):823-7.
[13]. Mogadam M, Dobbins III WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981 Jan 1;80(1):72-6.
[14]. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scandinavian journal of gastroenterology. 1983 Sep 1;18(6):735-42.
[15]. Crohn BB, Yarnis H, Korelitz BI. Regional ileitis complicating pregnancy. Gastroenterology. 1956 Dec 1;31(6):615-28.
[16]. Miller JP. Inflammatory bowel disease in pregnancy: a review. Journal of the Royal Society of medicine. 1986 Apr;79(4):221-5.
[17]. Norton RA, Patterson JF. Pregnancy and regional enteritis. Obstetrics & Gynecology. 1972 Nov 1;40(5):711-2.
[18]. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scandinavian journal of gastroenterology. 1983 Sep 1;18(6):735-42.
[19]. Martimbeau PW, Weich JS, Weiland LH. Crohn's disease and pregnancy. American journal of obstetrics and gynecology. 1975 Jul 15;122(6):746-9.
[20]. Vender RJ, Spiro HM. Inflammatory bowel disease and pregnancy. Journal of clinical gastroenterology. 1982 Jun 1;4(3):231-49.
[21]. Sorokin JJ, Levine SM. Pregnancy and inflammatory bowel disease: a review of the literature. Obstetrics and gynecology. 1983 Aug 1;62(2):247-52.
[22]. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. Journal of clinical gastroenterology. 1984 Jun 1;6(3):211-6.
[23]. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Annals of Internal Medicine. 1984 Sep 1;101(3):377-86.
[24]. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. British Medical Journal (Clinical research ed.). 1982 Oct 10;285(6347):1012.
[25]. Dew MJ, Harries AD, Evans BK, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. The Lancet. 1983 Oct 1;322(8353):801.
[26]. Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. British medical journal. 1979 Dec 12;2(6204):1553.
[27]. Järnerot G, Into-Malmberg MB, Esbjörner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scandinavian journal of gastroenterology. 1981 Aug 1;16(5):693-7.
[28]. Järnerot G, Andersen S, Esbjörner E, Sandström B, Brodersen R. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scandinavian journal of gastroenterology. 1981 Nov 1;16(8):1049-55.
[29]. Parlesak A, Schäfer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. Journal of hepatology. 2000 May 1;32(5):742-7.
[30]. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R, Sartor RB, Swanson C. Alcohol, intestinal bacterial growth, intestinal

permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol. 2008 Aug 1;42(5):349-61.

[31]. Lieber CS. Medical disorders of alcoholism. New England Journal of Medicine. 1995 Oct 19;333(16):1058-65.

[32]. Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). bmj. 2018 Nov 14;363.

[33]. Yeh CC, Wang HH, Chou YC, Hu CJ, Chou WH, Chen TL, Liao CC. High risk of gastrointestinal hemorrhage in patients with epilepsy: a nationwide cohort study. InMayo Clinic Proceedings 2013 Oct 1 (Vol. 88, No. 10, pp. 1091-1098). Elsevier.

[34]. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. InMayo Clinic Proceedings 2006 Nov 1 (Vol. 81, No. 11, pp. 1462-1471). Elsevier.

[35]. Reid MC, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Archives of internal medicine. 1999 Aug 9;159(15):1681-9.

[36]. Vickers NJ. Animal communication: when i'm calling you, will you answer too?. Current biology. 2017 Jul 24;27(14): R713-5.

[37]. Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, Lewis JD. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Digestive diseases and sciences. 2013 May;58(5):1322-8.

[38]. Han DY, Fraser AG, Dryland P, Ferguson LR. Environmental factors in the development of chronic inflammation: A case–control study on risk factors for Crohn's disease within New Zealand. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2010 Aug 7;690(1-2):116-22.

[39]. Octoratou M, Merikas E, Malgarinos G, Stanciu C, Triantafillidis JK. A prospective study of pre-illness diet in newly diagnosed patients with Crohn's disease. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2012 Jan 1;116(1):40-9.

[40]. Zutshi M, Hull TL, Hammel J. Crohn's disease: a patient's perspective. International Journal of Colorectal Disease. 2007 Dec;22(12):1437-44.

[41]. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, Dignass A, Fischer I, Fleig W, Fölsch UR, Herrlinger K. Diagnosis and therapy of ulcerative colitis: results of an evidence-based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Zeitschrift fur Gastroenterologie. 2004 Sep 1;42(9):979-83.

[42]. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C. European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006 Mar 1;55(suppl 1): i1-5.

[43]. Salma MS, Siva YS, Narendra JB, Narendra JB. Case Report on Ulcerative Colitis in 16-year girl. World Journal of Current Medical and Pharmaceutical Research. 2020 Sep 2:287-90.

[44]. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World journal of gastroenterology: WJG. 2014 Feb 2;20(5):1238.

[45]. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Official journal of the American College of Gastroenterology| ACG. 2011 Apr 1;106(4):563-73.

[46]. RAHIER JF, Yazdanpanah Y, Viget N, Travis S, COLOMBEL JF. influenza A (H1N1) virus in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2010 Jan;31(1):5-10.

[47]. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Official journal of the American College of Gastroenterology| ACG. 2010 Mar 1;105(3):501-23.

[48]. Walfish AE, Sachar DB. Ulcerative colitis. The Merck Manual website.

[49]. Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert review of gastroenterology & hepatology. 2018 Nov 2;12(11):1079-100.

[50]. Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World journal of gastroenterology. 2018 Sep 9;24(35):4014.

[51]. Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. The Lancet Child & Adolescent Health. 2017 Oct 1;1(2):147-58.

[52]. Liu CY, Polk DB. Microbiomes through the looking glass: what do UC?. Cell Host & Microbe. 2018 Oct 10;24(4):472-4.

[53]. Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RW, Paridaens K, Peyrin-Biroulet L, Scott G, Van Assche G, Wehkamp J. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach. Intestinal research. 2018 Oct;16(4):522.

[54]. Reid MC, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Archives of internal medicine. 1999 Aug 9;159(15):1681-9.

[55]. Swanson GR, Sedghi S, Farhadi A, Keshavarzian A. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol. 2010 May 1;44(3):223-8.

[56]. Terry R, Chintanaboina J, Patel D, Lippert B, Haner M, Price K, Tracy A, Lalos A, Wakeley M, Gutierrez LS. Expression of WIF-1 in inflammatory bowel disease.

[57]. Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, Sarmiento-Aguilar A, Barreto-Zuñiga R, Martínez-Benitez B, Lara-Velazquez MA. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. Journal of Inflammation. 2018 Dec;15(1):1-2.

[58]. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011 Jun;474(7351):307-17.

[59]. Colombel JF, Mahadevan U. Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology. 2017 Jan 1;152(2):309-12.

[60]. Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT. The cost of inflammatory bowel disease: an initiative from the Crohn's & Colitis Foundation. Inflammatory bowel diseases. 2020 Jan 1;26(1):1-0.

[61]. Meucci G, Vecchi M, Torgano G, Arrigoni M, Prada A, Rocca F, Curzio M, Pera A, De Franchis R, Gruppo di Studio per le Malattie Infiammatorie Intestinali. Familial aggregation of inflammatory bowel disease in northern Italy: a multicenter study. Gastroenterology. 1992 Aug 1;103(2):514-9.

[62]. Gordon H, Trier Moller F, Andersen V, Harbord M. Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies. Inflammatory bowel diseases. 2015 Jun 1;21(6):1428-34.

[63]. Luo Y, De Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, Lamb CA, McCarthy S, Ahmad T, Edwards C, Serra EG. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature genetics. 2017 Feb;49(2):186-92.

[64]. Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017 Jul;547(7662):173-8.

[65]. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature genetics. 2015 Mar;47(3):291-5.

[66]. Saint Pierre A, Génin E. How important are rare variants in common disease? Briefings in functional genomics. 2014 Sep 1;13(5):353-61.

[67]. Mancuso N, Rohland N, Rand KA, Tandon A, Allen A, Quinque D, Mallick S, Li H, Stram A, Sheng X, Kote-Jarai Z. The contribution of rare variation to prostate cancer heritability. Nature genetics. 2016 Jan;48(1):30-5.

[68]. De Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature genetics. 2017 Feb;49(2):256-61.

[69]. Bomba L, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common disease. Genome biology. 2017 Dec;18(1):1-7.

[70]. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World journal of cardiology. 2017 Feb 26;9(2):76.

[71]. Gulcher J. Microsatellite markers for linkage and association studies. Cold Spring Harbor Protocols. 2012 Apr 1;2012(4):pdb-top068510.

[72]. International Human Genome Sequencing Consortium. Correction: initial sequencing and analysis of the human genome. Nature. 2001 Aug 1;412(6846):565-6.

[73]. Shendure J, Findlay GM, Snyder MW. Genomic medicine–progress, pitfalls, and promise. Cell. 2019 Mar 21;177(1):45-57.

[74]. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. American journal of human genetics. 1996 Jun;58(6):1347.

[75]. Davis S, Schroeder M, Goldin LR, Weeks DE. Nonparametric simulation-based statistics for detecting linkage in general pedigrees. American journal of human genetics. 1996 Apr;58(4):867.

[76]. Whittemore AS, Halpern J. A class of tests for linkage using affected pedigree members. Biometrics. 1994 Mar 1:118-27.

[77]. Rannala B, Reeve JP. High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence. The American Journal of Human Genetics. 2001 Jul 1;69(1):159-78.

[78]. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). American journal of human genetics. 1993 Mar;52(3):506.

[79]. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. The American Journal of Human Genetics. 2000 Jul 1;67(1):146-54.

[80]. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001 May;411(6837):599-603.

[81]. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May;411(6837):603-6.

[82]. Altshuler D, Donnelly P, International HapMap Consortium. A haplotype map of the human genome. Nature. 2005 Oct 27;437(7063): nature04226.